Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Inclusion Criteria

• •Patients must have histologically or cytologically confirmed diagnosis of stage I, II or III non-small cell lung cancer; tissue blocks or slides will be requested
• •Patients must have surgically resectable disease and may not be treated with prior chemotherapy or radiation
• •Patients must be able to tolerate systemic chemotherapy prior to surgical resection
• •No acute intercurrent illness or infection
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• •Leukocytes \>= 3,000/uL
• •Absolute neutrophil count (ANC) \>= 1,500/uL
• •Platelets \>= 100,000/uL
• •Hemoglobin \>= 8g/dL
• •Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal
• •Bilirubin within normal institutional limits
• •Prior to study enrollment, all women of child-bearing potential must have a negative pregnancy test; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 2 months after the completion of therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
• •Patients with a history of non-melanoma skin cancer, or other malignancies treated 5 years or more prior to the current tumor, from which the patient has remained continually disease-free, are eligible
• •Ability to understand and the willingness to sign a written informed consent document